Ludwig Presence at 2019 AACR Annual Meeting

Ludwig Scientist(s) Affiliation(s) Session Time Presentation Time Location Session Type Session Title Presentation/Abstract Title

Friday, March 29

Clinical experience with Room A411 - Georgia World ED37 - Intersection of Radiation Michael A. Postow Ludwig MSK 5:15 - 7:15 PM 5:15 - 5:40 PM Education Session radiotherapy in the context of CC and Immune Therapy immune checkpoint blockade

Saturday, March 30

ED43 - Co-evolution of Tumor Marcus Auditorium- Bldg A- Chairperson and Mechanisms Kornelia Polyak* Ludwig Harvard 8:00 - 10:00 AM 8:00 AM - 10:00 AM Education Session and Microenvironment in GWCC underlying polyclonal metastases Metastasis ED10 - Vascular-Immune Cell Improving immunotherapy of Room A411 - Georgia World Rakesh K. Jain* Ludwig Harvard 8:00 - 10:00 AM 8:00 AM - 8:25 AM Education Session Crosstalk: Implications for cancer by normalizing tumor CC Cancer Immunotherapy vessels Targeting the tumor ED10 - Vascular-Immune Cell Room A411 - Georgia World microenvironment for treatment of Tatiana Petrova Ludwig Lausanne 8:00 - 10:00 AM 9:00 - 9:45 AM Education Session Crosstalk: Implications for CC chemo-resistant desmoplastic Cancer Immunotherapy colon cancer MW13 - Methods to Study Chairperson and Importance of 10:15 - 10:16 AM and Georgia Ballrm 1- Bldg C- Matthew G. Vander Heiden Ludwig MIT 10:15 AM - 12:15 PM Methods Workshop Metabolism for Cancer tissue context in understanding 10:15 - 10:35 AM GWCC Research metabolic vulnerabilities ED28 - ctDNA for Cancer Room B312 - Georgia World Stratification, Monitoring, Clonal ctDNA and cfDNA in body fluids as Nickolas Papadopoulos Ludwig Johns Hopkins 3:15 - 5:15 PM 3:15 - 3:40 PM Education Session CC Tracking, MRD Detection, and cancer biomarkers Early Diagnosis

Sunday, March 31

Room A311 - Georgia World Pier Paolo Pandolfi* Ludwig Harvard 7:00 - 8:00 AM 7:00 AM - 8:00 AM Meet-the-Expert Session ME41 - Title to Be Announced Title to be announced CC PL01 - Opening Plenary: PL01-05 - Next-generation CAR T Achieving Equitable Patient Crystal L. Mackall Ludwig Stanford 9:45 AM - 12:15 PM 11:15 - 11:40 AM Hall A - Convention Center Plenary Session cells designed to overcome tumor Care through Precision and resistance Convergent Cancer Science Molecular and spatial NIH03 - Towards the Room A406 - Georgia World NCI/NIH-Sponsored characterization of human tumors: Peter K. Sorger Ludwig Harvard 2:00 - 3:30 PM 2:10 PM - 2:25 PM Generation of Spatial Human CC Session Multiplexed protein imaging in intact Tumor Maps tissue sections using CycIF

969 - Characterization of murine MS.TB02.01 - Novel mammary epithelial populations Room A404 - Georgia World Joan S. Brugge** Ludwig Harvard 3:00 - 5:00 PM 3:35 PM - 3:50 PM Minisymposium Approaches to Understand throughout development and in CC Cancer Stem Cells premalignant tissue via mass cytometry 907 - Bioinformatic method to Room B206 - Georgia World MS.BSB01.01 - Tools for define epigenetically regulated Cigall Kadoch Ludwig Harvard 3:00 - 5:00 PM 3:35 PM - 3:50 PM Minisymposium CC Cancer Genome Analysis enhancer elements associated with cancer Room B206 - Georgia World MS.BSB01.01 - Tools for 910 - The cBioPortal for cancer Chris Sander Ludwig Harvard 3:00 - 5:00 PM 4:20 PM - 4:35 PM Minisymposium CC Cancer Genome Analysis genomics

949 - ARID1A is a critical regulator Room A302 - Georgia World MS.MCB05.01 - Emerging of luminal identity and therapeutic Cigall Kadoch Ludwig Harvard 3:00 - 5:00 PM 3:35 PM - 3:50 PM Minisymposium CC Targets in Cancer Epigenetics response in estrogen receptor- positive CT037 - Genomic analyses and F. Stephen Hodi, Jedd D. Ludwig Harvard and Room A411 - Georgia World Clinical Trials CTMS01 - Advances in Novel 3:00 - 5:00 PM 3:00 - 5:00 PM immunotherapy in advanced Wolchok Ludwig MSK CC Minisymposium Immunotherapeutics Andrew Chow*, Sadna Budhu, 978 - Tim-4+ tissue-resident Hong Zhong, Jason S. Lewis, Room B312 - Georgia World MS.TB06.01 - The Immune Ludwig MSK 3:00 - 5:00 PM 3:00 - 5:00 PM Minisymposium macrophages impair antitumor T- Jedd D. Wolchok**, Taha CC Microenvironment in Cancer cell immunity Merghoub** MG06 - Meet the Editor-in-Chief AACR Pubs Booth 3226 - Hall Chi Van Dang* The Ludwig Institute 4:00 - 5:00 PM 4:00 PM - 5:00 PM Meet and Greet of Cancer Research: Chi Van Invited Speaker B Dang, MD, PhD PAS06 - Personalized Career Professional Conversations: Pathways to Jedd D. Wolchok Ludwig MSK 5:00 - 7:00 PM 5:00 - 7:00 PM International Ballrm N - Hyatt Advancement Session Mentor Academia, Industry, and Government TM06 - Pediatric Cancer Working Group (PCWG) Town Crystal L. Mackall Ludwig Stanford 6:30 - 8:30 PM 6:30 - 8:30 PM Town Meeting Town Meeting Chairperson and Moderator Hall Meeting and Networking Reception

Monday, April 1

Room B302 - Georgia World ME48 - Approaches to Approaches to combination Peter K. Sorger Ludwig Harvard 7:00 - 8:00 AM 7:00 AM - 8:00 AM Meet-the-Expert Session CC Combination Therapy therapy Cistrome mining for new Room B405 - Georgia World SY43 - Systems Epigenetics in Myles Brown Ludwig Harvard 10:30 AM - 12:15 PM 11:05 AM - 11:30 AM Major Symposium therapeutic targets in hormone- CC Hormone-Driven dependent cancers Room B401 - Georgia SY37 - Circadian Rhythms and MYC, clock function, and metabolic Chi Van Dang* The Ludwig Institute 10:30 AM - 12:15 PM 10:35 AM - 11:00 AM Major Symposium World CC Cancer vulnerabilities of cancer SY48 - Women in Cancer Research Scientific Ludwig Board of Room A313 - Georgia World Symposium: Advances in Nancy E. Davidson* 1:00 - 2:45 PM 1:05 PM - 1:30 PM Major Symposium Invited Speaker Directors CC Genetics, Diagnosis, and Therapeutics among Common Cancers in Women Chairperson and Transient 1:00 - 1:01 PM and 1:00 - Georgia Ballrm 1- Bldg C- Advances in Diagnostics ADT11 - Clonal Cooperation in commensalism drives solid Joan S. Brugge Ludwig Harvard 1:00 - 2:45 PM 1:25 PM GWCC and Therapeutics Cancer peritoneal metastasis in a model of ovarian clear cell carcinoma SY45-313 - The Next SY45-04 - Development of Benjamin Izar*, F. Stephen Hodi, Marcus Auditorium- Bldg A- Generation of Precision Cancer Ludwig Harvard 1:00 - 2:45 PM 1:55 PM - 2:10 PM Major Symposium therapeutic strategies by resolving Peter K. Sorger, Asaf Rotem GWCC Medicine: Recognizing and the tumor ecosystem Exploiting the Complexity From evolutionary mathematical SY38 - Evolution and modeling to clinical validation in Franziska Michor* Ludwig Harvard 1:00 - 2:45 PM 2:05 PM - 2:30 PM Murphy Ballrm- Bldg B- GWCC Major Symposium Development of Resistance to patients: Lessons Therapy learned SY17 - Minimal Residual Room B206 - Georgia World SY17-02 - Solid tumor cancer stem Michael F. Clarke Ludwig Stanford 1:00 - 2:45 PM 1:35 - 2:00 PM Major Symposium Disease: From Bench to CC cells: From bench to bedside Bedside AOS02 - Emerging Georgia Ballrm 3- Bldg C- Advances in Organ Site Crystal L. Mackall Ludwig Stanford 1:00 - 2:45 PM 1:00 - 1:01 PM Immunotherapies for Childhood Chairperson GWCC Research Cancer Divergent resistance mechanisms Franziska Michor, Kornelia Georgia Ballrm 1- Bldg C- SS09 - NextGen Stars Spotlight Ludwig Harvard 3:00 - 4:30 PM 3:00 PM - 3:20 PM Special Session to HER2-targeted therapies in Polyak** GWCC 2: Site-Specific Cancers breast cancer

*scientist is lead author **scientist is senior author 1 701 - Functionally specialized MS.IM01.01 - Immune Cell subsets of exhausted CD8+ T F. Stephen Hodi, Arlene H. Room B405 - Georgia World Ludwig Harvard 3:00 - 5:00 PM 3:20 PM - 3:35 PM Minisymposium Subsets in the Suppressive cells mediate tumor control and Sharpe CC Tumor Microenvironment differentially respond to checkpoint blockade 2744 - Blocking CXCR4 alleviates desmoplasia, increases T- Room A404 - Georgia World MS.TB06.02 - Signaling in the Ivy Chen*, Rakesh K. Jain** Ludwig Harvard 3:00 - 5:00 PM 3:35 PM - 3:50 PM Minisymposium lymphocyte infiltration, and CC Tumor Microenvironment improves immunotherapy in metastatic breast cancer CT131 - Entrectinib in NTRK- fusion positive (NTRK-FP) non- CTMS02 - The Next Generation small cell (NSCLC): Marcus Auditorium- Bldg A- Clinical Trials George D. Demetri** Ludwig Harvard 3:00 - 5:00 PM 4:05 - 4:20 PM of Clinical Trials in Molecularly- Integrated analysis of patients GWCC Minisymposium driven Therapy enrolled in three trials (STARTRK- 2, STARTRK-1 and ALKA-372- 001) Roberta Zappasodi*, Cailian Liu, Xia Yang, Hong Zhong, Jingjing MS.IM02.01 - Rational Room A411 - Georgia World 2711 - Rational combination of Qi, Philip Wong, Margaret K. Ludwig MSK 3:00 - 5:00 PM 3:00 - 5:00 PM Minisymposium Combinations of CC GITR agonism with PD-1 blockade Callahan, Jedd Wolchok, Taha Immunotherapy Merghoub** Room B408 - Georgia World Late-Breaking LBMS02 - Minisymposium: Late- LB-146 / 3 - Phase I CD22 CAR T- Crystal L. Mackall Ludwig Stanford 3:00 - 5:00 PM 3:35 - 3:50 PM CC Minisymposium Breaking Research 2 cell trial updates The early days of immune SS05 - Making Science Count checkpoint inhibition: Reducing Jedd D. Wolchok Ludwig MSK 5:00 - 6:30 PM 5:00 - 6:30 PM Hall A - Convention Center Special Session for Patients: From T-Cell CTLA-4 blockade to clinical Signaling to CTLA-4 Approval practice

Tuesday, April 2

SY21-03 - Shutting off cancer's SY21 - Tumor Metabolism and fountain of youth: Targeting Stephen J. Kron** Ludwig 10:30 AM - 12:15 PM 11:35 AM - 12:00 PM Murphy Ballrm- Bldg B- GWCC Major Symposium DNA Damage Response metabolism to block repair and reverse immortality SY23 - Metastasis: Evidence SY23-02 - Actions of the EMT Room B312 - Georgia World Robert A. Weinberg Ludwig MIT 10:30 AM - 12:15 PM 11:05 - 11:30 AM Major Symposium and Clinical Implications of Early Program in fostering malignant CC Dissemination progression SYPOL05 - ACCELERATE-ing Room A402 - Georgia World Crystal L. Mackall Ludwig Stanford 10:30 AM - 12:15 PM 10:30 - 10:31 AM Major Symposium Pediatric Oncology Drug Chairperson CC Discovery and Development SY41-144 - Advancing Ludwig Board of Marcus Auditorium- Bldg A- Prospects for epigenetic therapy Nancy E. Davidson 1:00 - 2:45 PM 2:05 PM - 2:30 PM Major Symposium Epigenetic Therapies for Solid Directors GWCC for breast cancer Tumors Chairperson and SY33-01 - 1:00 PM - 1:01 PM and Georgia Ballrm 3- Bldg C- SY33 - Vascular Regulation of Improving immunotherapy of Rakesh K. Jain* Ludwig Harvard 1:00 - 2:45 PM Major Symposium 1:05 PM - 1:30 PM GWCC Antitumor Immunity cancer by normalizing tumor vessels ADT16 - Tumor Treating Fields: Identification of a new mechanism Georgia Ballrm 2- Bldg C- Advances in Diagnostics Sanjiv Sam Gambhir Ludwig Stanford 1:00 - 2:45 PM 1:00 - 1:25 PM A Fourth Modality in Cancer for how tumor treating fields effect GWCC and Therapeutics Treatment tumor cells 4490 - PARP inhibitor efficacy depends on CD8+ T-cell Room A411 - Georgia World MS.IM02.02 - Tumor Immune Jennifer L. Guerriero Ludwig Harvard 3:00 - 5:00 PM 3:00 PM - 5:00 PM Minisymposium recruitment via the STING CC Microenvironment pathway in BRCA-deficient models of triple-negative breast cancer

4487 - Association of the tumor- Jia R. Lin, Sandro Santagata, immune microenvironment with Room A411 - Georgia World MS.IM02.02 - Tumor Immune Peter K. Sorger, Alan D. Ludwig Harvard 3:00 - 5:00 PM 3:00 PM - 5:00 PM Minisymposium response to niraparib and CC Microenvironment D’Andrea pembrolizumab in relapsed, platinum-resistant ovarian cancer MS.ET04.01 - Genomic Room B312 - Georgia World Anthony G. Letai* Ludwig Harvard 3:00 - 5:00 PM 3:00 PM - 3:01 PM Minisymposium Correlates of Therapy Chairperson CC Response MS.ET04.01 - Genomic 4478 - High-throughput dynamic Jennifer Guerriero, George Room B312 - Georgia World Ludwig Harvard 3:00 - 5:00 PM 3:00 PM - 5:00 PM Minisymposium Correlates of Therapy BH3 profiling identifies active Demetri, Anthony Letai** CC Response cancer therapies in solid tumors

CT232 - Phase I combination study of the CHK1 inhibitor CTMS03 - Developmental Marcus Auditorium- Bldg A- Clinical Trials prexasertib (LY2606368) and Alan D. D'Andrea Ludwig Harvard 3:00 - 5:00 PM 3:05 - 3:20 PM Therapeutics: Clinical Results GWCC Minisymposium olaparib in patients with high-grade of Novels Agents serous ovarian cancer and other advanced solid tumors

Room A406 - Georgia World NCI/NIH-Sponsored NIH13 - Liquid Biopsy: A Holy Potential clinical application of liquid Nickolas Papadopoulos Ludwig Johns Hopkins 2:45 - 4:15 PM 2:45 - 4:15 PM CC Session Grail of Early Detection biopsy in early detection

Room A404 - Georgia World MS.EP01.01 - Factors 4470 - Aneuploidy drives lethal Angelika Amon** Ludwig MIT 3:00 - 5:00 PM 3:00 - 5:00 PM Minisymposium CC Influencing Cancer Outcomes progression in prostate cancer

Wednesday, April 3

10:15 - 10:16 AM and Room B405 - Georgia World Chairperson and The role of Angelika Amon Ludwig MIT 10:15 AM - 12:00 PM Major Symposium SY39-263 - Genomic Instability 10:20 - 10:45 AM CC aneuploidy in tumorigenesis

Room B405 - Georgia World Characterizing tumor evolution one Tyler Jacks Ludwig MIT 10:15 AM - 12:00 PM 10:50 - 11:15 AM Major Symposium SY39-263 - Genomic Instability CC cell at a time

SY06 - Novel Insights in the Deconvoluting cellular Georgia Ballrm 3- Bldg C- Molecular Pathogenesis and Ash A. Alizadeh Ludwig Stanford 10:15 AM - 12:00 PM 10:50 - 11:15 AM Major Symposium determinants of antitumor immune GWCC Monitoring of Malignant recognition Lymphomas

*scientist is lead author **scientist is senior author 2 Ludwig Presence at 2019 AACR Annual Meeting - Poster Sessions

Ludwig Scientist(s) Affiliation(s) Session Time Presentation Time Location Session Type Session Title Presentation/Abstract Title

Sunday, March 31

247 / 10 - Identification of the GABAA receptor in melanoma PO.ET01.02 - Brain Cancers brain metastases patient tumors Benjamin Izar Ludwig Harvard 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 10 Poster Session and Neuroblastoma and demonstration that it is a viable drug target using benzodiazepine- derivatives

700 / 4 - Development of a second- generation TRAIL agonist and Peter Sorger Ludwig Harvard 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 32 Poster Session PO.MCB02.01 - Apoptosis predictive biomarker profile for 489 / 2 - Multi-parameter tissue section imaging and retrieval of PO.IM01.05 - Imaging the Jia-Ren Lin, Peter Sorger Ludwig Harvard 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 20 Poster Session image-defined micro-regions for Tumor Microenvironment RNA sequencing using the RareCyte® platform 139 / 16 - Single-cell RNA sequencing reveals compromised PO.TB06.04 - Gene Expression Jennifer Guerriero Ludwig Harvard 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 6 Poster Session immune microenvironment in in the Tumor Microenvironment precursor stages of multiple myeloma 2 / 2 - Discovery of BAY 2402234 by phenotypic screening: A human PO.CH01.01 - Novel Small Dihydroorotate Dehydrogenase David T. Scadden Ludwig Harvard 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 11 Poster Session Molecules for Cancer Therapy (DHODH) inhibitor in clinical trials for the treatment of myeloid

PO.MCB11.01 - Targeting 884 / 10 - Interplay between NRF2 Joan S. Brugge** Ludwig Harvard 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 38 Poster Session Oxidative Stress and and GPX4 is critical for cancer cell Senescence survival in 3D spheroids 260 / 4 - Identifying cancer drug PO.ET04.01 - Cell Death and sensitivity using live cell imaging Anthony Letai Ludwig Harvard 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 11 Poster Session DNA Repair Pathways dynamic BH3 profiling of solid tumor core biopsies 675 / 8 - Network modeling of PO.BSB02.01 - Convergence drug resistance mechanisms and Anthony G. Letai Ludwig Harvard 1:00 - 5:00 PM 1:00 - 5:00 PM Section 30 Poster Session Science for Therapeutics and drug combinations in breast Precision Medicine cancer 368A / 30 - Functional assessment of DNA damage PO.ET01.03 - New Anticancer repair defects and the anti-tumor Alan D. D'Andrea** Ludwig Harvard 1:00 - 5:00 PM 1:00 - 5:00 PM Section 14 Poster Session Agents immune response in high grade serous ovarian cancers using patient-derived organoids Yibin Liu*, Gergana Velikova, 825 / 11 - TAPS: A bisulfite- Marketa Tomkova, Benjamin PO.MCB05.04 - New Trends in free, base-resolution and Ludwig Oxford 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 36 Poster Session Schuster-Boeckler, Chun-Xiao DNA Methylation quantitative sequencing method for Song** cytosine modifications Skirmantas Kriaucionis*, Marketa Tomova, Sophie 835 / 21 - Altered DNA Kirschner, Mankgopo Kgatle, PO.MCB05.04 - New Trends in modifications in Barrett’s Ludwig Oxford 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 36 Poster Session Richard Owen, Michael White, DNA Methylation oesophagus and oesophageal Benjamin Schuster-Boeckler, Xin adenocarcinoma Lu* 331 / 22 - Dynamic kinome targeting reveals kinases involved PO.ET03.01 - Drug Resistance Frank Furnari Ludwig San Diego 1:00 - 5:00 PM 1:00 - 5:00 PM Section 13 Poster Session in acquired resistance to tyrosine 1 kinase inhibitors in EGFR-driven 250 / 13 - Tumor treating fields PO.ET01.02 - Brain Cancers Sanjiv S. Gambhir** Ludwig Stanford 1:00 - 5:00 PM 1:00 - 5:00 PM Section 10 Poster Session increases membrane permeability and Neuroblastoma in glioblastoma cells

Monday, April 1

1016 / 17 - The androgen receptor PO.EN01.01 - Endocrine- splice variant AR-V7 associates Geoffrey Greene Ludwig Chicago 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 2 Poster Session related Cancers with the glucocorticoid receptor following androgen blockade 1553 / 22 - Collagen affinity PO.IM02.17 - Therapeutic improves safety and efficacy of Stephen J. Kron Ludwig Chicago 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 25 Poster Session Antibodies 2 antibody and cytokine cancer immunotherapies PO.EN01.01 - Endocrine- PO.EN01.01 - Endocrine-related Marc Hafner Ludwig Harvard 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 2 Poster Session related Cancers Cancers LB-101 / 21 - Combined LBPO.MCB01 - Late-Breaking dynamics and post-translational Late-Breaking Poster Galit Lahav** Ludwig Harvard 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 42 Research: Molecular and modifications determine Session Cellular Biology / Genetics 1 subsequent protein expression and cell fate 1653 / 4 - Application of high- PO.BSB01.03 - Laboratory and density tiling CRISPR screen Cigall Kadoch Ludwig Harvard 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 31 Poster Session Computational Methods for technology to identify chromatin Cancer Analysis remodeler complex targets for drug discovery 1132 / 4 - Multiplexed immunofluorescence and multispectral imaging-based PO.TB07.01 - Novel Imaging Bradley E. Bernstein Ludwig Harvard 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 7 Poster Session quantification of tumor and immune Targets cell populations reveals spatial relationships in oral cavity squamous cell carcinoma PO.ET02.03 - Cellular 2978 / 26 - Clinical evaluation Joan S. Brugge** Ludwig Harvard 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 10 Poster Session Responses to Anticancer of lapatinib induced BCL-2 adaptive Agents 3: Novel Targets responses 1065 / 16 - Comprehensive molecular and experimental Ludwig Scientific Victor Velculescu 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 4 Poster Session PO.TB01.03 - Human in Mouse characterization of ovarian clear Advisor cell carcinoma cell lines for in vivo drug development TBA1431 / 12 - In vivo CRISPR/Cas9 screen of PO.IM02.15 - Adoptive Cell adoptively transferred T cells Tyler Jacks** Ludwig MIT 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 21 Poster Session Therapy 1 reveals novel mediators of exhaustion and immunosuppression LBPO.MCB01 - Late-Breaking LB-081 / 1 - A nuclear cAMP Jedd D. Wolchok, Taha Late-Breaking Poster Ludwig MSK 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 42 Research: Molecular and microdomain functions as a tumor Merghoub Session Cellular Biology / Genetics suppressor in melanoma

*scientist is lead author **scientist is senior author 3 PO.ET02.02 - Cellular 2068 / 5 - A highly selective Responses to Anticancer dual Haspin-kinase and PIM- Peter K. Sorger, Benjamin Izar** Ludwig Harvard 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 10 Poster Session Agents 2 / Overcoming inhibitor overcomes RAF/MEK- Resistance inhibitor resistance in melanoma LB-113 / 8 - MAPK pathway suppression unmasks latent DNA LBPO.ET01 - Late-Breaking Stephen Elledge, Karen Late-Breaking Poster repair defects and confers a Ludwig Harvard 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 40 Research: Experimental and Cichowski** Session chemical synthetic vulnerability Molecular Therapeutics 1 inBRAF,NRASandNF1-mutant 3775 / 8 - Characterization of intratumoral heterogeneity in drug sensitivity and modeling of drug PO.TB10.02 - Tumor Evolution Joan S. Brugge** Ludwig Harvard 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 7 Poster Session combination effects using and Heterogeneity 2 subclonal cell populations derived from a single breast cancer cell line 2615 / 21 - Systematic approaches to predict oncogenic transcriptional PO.MCB04.02 - Oncogenic Myles Brown Ludwig Harvard 1:00 - 5:00 PM 1:00 - 5:00 PM Section 37 Poster Session regulatory circuitries identify Transcription Factor Function important nodes in high-grade serous ovarian cancer

3779 / 12 - Clonal tracing reveals PO.TB10.02 - Tumor Evolution Myles Brown Ludwig Harvard 1:00 - 5:00 PM 1:00 - 5:00 PM Section 7 Poster Session different mechanisms of resistance and Heterogeneity 2 to immune checkpoint blockade

2496 / 6 - Dynamic BH3 profiling PO.MCB02.03 - BCL-2 Family identifies active combinations with Anthony G. Letai** Ludwig Harvard 1:00 - 5:00 PM 1:00 - 5:00 PM Section 32 Poster Session Proteins conventional chemotherapy in non- small cell lung cancer 2101 / 8 - Targeting the root of PO.ET03.03 - Drug Resistance Joan S. Brugge Ludwig Harvard 1:00 - 5:00 PM 1:00 - 5:00 PM Section 7 Poster Session cancer persister cells using an 3 expressed barcode library 2450 / 15 - Single-cell profiling PO.BSB02.03 - Convergence reveals programs mediating Science for Tumor Biology, oncogenic kinase-independence Scott R. Manalis Ludwig MIT 1:00 - 5:00 PM 1:00 - 5:00 PM Section 30 Poster Session Molecular Biology, and and minimal residual disease in Microenvironment BCR-ABL-rearranged acute lymphoblastic leukemia 2402 / 26 - GITR cancer immunotherapy: Epitope swapping Roberta Zappasodi*, Jedd D. PO.IM02.18 - Therapeutic Ludwig MSK 1:00 - 5:00 PM 1:00 - 5:00 PM Section 25 Poster Session of anti-GITR TRX518 to inform Wolchok, Taha Merghoub** Antibodies 3 functional translatability from mouse to human Session LBPO.ET01 - Late- LB-110 / 5 - Proteasome addiction Jorge A. Benitez*, Jianhui Ma, Late-Breaking Poster Breaking Research: Ludwig San Diego 1:00 - 5:00 PM 1:00 - 5:00 PM Section 40 a new therapeutic opportunity to Tomoyuki Koga, Frank Furnari** Session Experimental and Molecular treat PTEN-deficient brain tumors Therapeutics 1

Tuesday, April 2

3597 / 13 - BAY 2402234: Preclinical evaluation of a novel, Section 39 PO.MCB08.04 - Targeting selective dihydroorotate David T. Scadden Ludwig Harvard 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Poster Session Metabolism for Cancer Therapy dehydrogenase (DHODH) inhibitor for the treatment of diffuse large B- cell lymphoma (DLBCL)

3451 / 22 - Interpreting gene lists Chris Sander Ludwig Harvard 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 33 Poster Session PO.MCB01.05 - 1 from -omics experiments 2867 / 3 - MDM2 and MDM4 are PO.TB08.01 - Targets and Peter J. Park Ludwig Harvard 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 6 Poster Session therapeutic vulnerabilities in Therapies in Pediatric Cancer malignant rhabdoid tumors 3257 / 7 - Activation of CD137 PO.IM02.11 - Novel Peter Park Ludwig Harvard 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 25 Poster Session using multivalent and tumor Immunomodulatory Agents 1 targeted Bicyclic peptides PO.ET01.07 - Diagnostics, 2990 / 12 - Individualized functional Anthony Letai** Ludwig Harvard 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 11 Poster Session Biomarkers, and the Tumor approach to tailoring acute myeloid Microenvironment leukemia therapy LB-194 / 12 - First-in-human Phase I study of the CD40 agonist Late-Breaking Poster LBPO.IM02 - Late-Breaking mAb CDX-1140 and in combination Danny Khalil Ludwig MSK 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 42 Session Research: 2 with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results 3019 / 11 - Dynamic kinome profiling of EGFRvIII-driven murine Session PO.ET03.04 - Drug Frank Furnari Ludwig San Diego 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 12 Poster Session astrocyte models of glioblastoma Resistance 4 reveals targets for dual kinase inhibitor therapy 4432 / 26 - Multi-omics profiling PO.MCB06.02 - Targeting the establishes the polypharmacology Marc A. Hafner, Peter K. Cell Cycle: Development of Ludwig Harvard 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 37 Poster Session of FDA Approved CDK4/6 Sorger** Preclinical Models and inhibitors and its impact on drug Therapeutic Targets response

3820 / 25 - Discovery of adaptive resistance pathways and anti- PO.ET03.05 - Drug Resistance Chris Sander Ludwig Harvard 1:00 - 5:00 PM 1:00 PM - 5:00 PM Section 10 Poster Session resistance combination therapies 5 from phosphoproteomic data using graphical models 4358 / 6 - Characterization of PO.MCB08.03 - Metabolic primary and metastatic pancreatic Matthew Vander Heiden Ludwig MIT 1:00 - 5:00 PM 1:00PM - 5:00 PM Section 35 Poster Session Reprogramming in Cancer tumors in pancreatic ductal adenocarcinoma (PDAC) PO.TB09.02 - Radiation Tissue 3735 / 12 - An anti-tumor immune Jedd Wolchok, Taha Merghoub, Ludwig MSK 1:00 - 5:00 PM 1:00PM - 5:00 PM Section 5 Poster Session Tolerance, Immunity, and in response is evoked by partial- Sadna Budhu Vivo Effects of Radiation volume single dose radiation

4041 / 4 - Coupling neoantigen specific T cell clonotypes and their Taha Merghoub, Jedd D. Ludwig MSK + Ludwig PO.IM02.09 - Biomarkers and 1:00 - 5:00 PM 1:00PM - 5:00 PM Section 22 Poster Session molecular phenotypes at the single Wolchok, Victor E. Velculescu Scientific Advisor Immune Monitoring cell level in resectable anti-PD-1 treated NSCLC

Session PO.MCB05.02 - 4334 / 22 - Epigenetic Yang Li Ludwig San Diego 1:00 - 5:00 PM 1:00PM - 5:00 PM Section 33 Poster Session Epigenetic Changes as reprogramming of tissue-specific Molecular Markers transcription promotes metastasis

LB-231 / 10 - Genome-wide cell- Ludwig Scientific Late-Breaking Poster LBPO.CL02 - Late-Breaking free DNA fragmentation as a Victor Velculescu** 1:00 - 5:00 PM 1:00 - 5:00 PM Section 41 Advisor Session Research: Clinical Research 2 biomarker for early detection of cancer 3977 / 3 - Clinical validation of cell- PO.CL11.06 - Novel Strategies free circulating tumor DNA to Ludwig Scientific Victor Velculescu 1:00 - 5:00 PM 1:00 - 5:00 PM Section 19 Poster Session for Biomarker Identification and detect therapy resistance and Advisor Use in Cancer 2 disease progression in metastatic colorectal cancer patients 4041 / 4 - Coupling neoantigen specific T cell clonotypes and their Ludwig Scientific PO.IM02.09 - Biomarkers and Victor Velculescu 1:00 - 5:00 PM 1:00 - 5:00 PM Section 22 Poster Session molecular phenotypes at the single Advisor Immune Monitoring cell level in resectable anti-PD-1 treated NSCLC

*scientist is lead author **scientist is senior author 4 Wednesday, April 3

4738 / 28 - Lipid peroxidation PO.ET06.08 - DNA Repair and mediates the effects of Stephen J. Kron** Ludwig Chicago 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 10 Poster Session Reactive Agents / HDAC / topoisomerase poisons on their Demethylating Agents targets 4832 / 20 - Preclinical evaluation of neratinib plus T-DM1 PO.ET07.01 - Targeted Sheheryar Kabraji Ludwig Harvard 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 14 Poster Session in orthotopic PDX models of HER2- Therapies positive breast cancer brain metastases 5186 / 4 - Discovery of a novel Ludwig Harvard, PO.MCB05.03 - Deregulation of Anthony Letai, Michael Hemann 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 35 Poster Session histone deacetylase 6 inhibitor that Ludwig MIT Histone Modifications kills drug-resistant breast cancer

PO.CL11.07 - Novel Strategies 4885 / 8 - AL101 mediated tumor Jon Aster Ludwig Harvard 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 19 Poster Session for Biomarker Identification and inhibition in Notch mutated ACC Use in Cancer 3 PDX models

5108 / 16 - Somatic small variant PO.BSB01.05 - Methods and David Benjamin Ludwig MIT 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 30 Poster Session and copy number alteration calling Tools for Cancer Analysis with the Genome Analysis Toolkit

Deciphering the causes of the PO.TB11.01 - Mutagenesis, COSMIC mutational signature 17 Marketa Tomkova* Ludwig Oxford 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 7 Poster Session Chemical , and by combining pan-cancer data with Tumor Initiation/Promotion experimental mouse models PO.ET07.03 - Targeted 4843 / 1 - TP53-stabilization with Arnab Ghosh*, Hong Zhong, Therapies and APR-246 enhances antitumor Sadna Budhu, Jedd Wolchok, Ludwig MSK 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 15 Poster Session Immunological/Tumor effects of immune checkpoint Taha Merghoub** Microenvironment Effects blockade in preclinical models 5130 / 9 - Single-cell mutational profiling of paired AML samples at PO.MCB09.07 - Advanced Ravindra Majeti** Ludwig Stanford 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 32 Poster Session diagnosis, remission and relapse: Omics Implications for therapeutic resistance and MRD detection

5271 / 14 - Molecular imaging of pyruvate kinase M2 (PKM2) with PO.MCB08.05 - Tracking [18F]DASA-23 detects Sanjiv S. Gambhir** Ludwig Stanford 8:00 AM - 12:00 PM 8:00 AM - 12:00 PM Section 38 Poster Session Metabolic Profiles and Subtype- temozolomide- and tumor treating specific Metabolic Interventions fields (TTFields)-induced changes in glycolysis in glioblastoma

*scientist is lead author **scientist is senior author 5